Tuberculosis Treatment Drugs Market by Disease Type (Active Tuberculosis and Latent Tuberculosis), Therapy Type (First Line Therapy and Second Line Therapy), and Distribution Channel (Hospital Pharmacy, Drug Store, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021–2030

Tuberculosis Treatment Drugs Market Outlook 2030

Tuberculosis is an infectious disease which is caused due to mycobacterium tuberculosis. Tuberculosis usually affects lungs, throats, and other parts of body. Blood containing mucous, fever, night sweats, continuous cough, and weight loss are the common symptoms of tuberculosis. Tuberculosis can be spread through air when active tuberculosis patient coughs, spit, speak or sneeze. People with latent tuberculosis do not spread the diseases. Infection worsens if patients have HIV and smoke tobacco. In latent tuberculosis isoniazid and rifampicin are prescribed for treatment. Moreover in active tuberculosis isoniazid, pyrazinamide, ethambutol, and rifampicin are administered to the patient.

Market Scope and Structure Analysis

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on tuberculosis treatment drugs market.

Top Impacting Factors

• Increase in outbreak of infectious diseases, surge in reoccurrence of tuberculosis, rise cases of hospital acquired infections, lack of sanitization practices, increase in consumption of tobacco & cigarettes, and surge in cases of chronic diseases such as AIDS and diabetes are the key factors that drive the growth of tuberculosis treatment drugs market.
• In addition, rise in demand for effective tuberculosis treatment procedures, government support to promote manufacturing anti tuberculosis drugs, surge in launch of novel therapies in market, increase in adoption of modern healthcare services, rise in usage of targeted drug therapies, surge in cases of multi drug resistant tuberculosis, and increase in mortality rate due to tuberculosis are some factors that fuel the growth of tuberculosis treatment drugs market.
• However, increase in number of drug recall and high pricing of tuberculosis treatment drugs restrain the growth of tuberculosis treatment drugs market.
• Contrarily, government initiatives for fast track regulatory approvals and favourable reimbursement policies are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2019, Mylan Pharmaceutical announced launch of Pretomanid drug. This drug can be used in treatment of pulmonary tuberculosis.

In 2019, TB alliance announced approval of the U.S. Food and Drug Administration for the launch of Pretomanid drug with combination of bedaquiline and linezolid. This medication can be used in treatment of chronic tuberculosis.

Key Segments

Key Benefits of the Report

• This study presents the analytical depiction of tuberculosis treatment drugs market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the tuberculosis treatment drugs market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the tuberculosis treatment drugs market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Tuberculosis Treatment Drugs Market Report           

• Which are the leading players active in the tuberculosis treatment drugs market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is "tuberculosis treatment drugs"?
• What is "tuberculosis treatment drugs" market prediction in the future?
• Who are the leading global players in the "tuberculosis treatment drugs" market?
• What are the current trends and predicted trends?
• What are the key benefits of the "tuberculosis treatment drugs" market report?

 Key Market Segments

 Key Market Players

• Johnson & Johnson Services, Inc.
• Lupin Ltd
• Novartis AG
• Macleods Pharmaceuticals Ltd.
• Otsuka Pharmaceutical Co., Ltd
• Pfizer Inc.
• AstraZeneca Plc
• Cipla Ltd
• Alkem Laboratories Ltd
• Mylan